Newsroom

Stay up to date with what’s happening at ONO PHARMA USA.

Doctor meeting with a patient
Ono Pharmaceutical Co., Ltd. Announced FY2025 Q3 Financial Results
Management / Finance
February 2, 2026
Ono Pharmaceutical co., ltd. Receives Highest A-List Rating in CDP 2025 Report for Climate Change and Water Security Efforts
Sustainability
December 11, 2025
Ono Pharmaceutical Co., Ltd. Announced FY2025 Q2 Financial Results
Management / Finance
October 30, 2025
Ono Pharmaceutical Co., Ltd. AnnouncedONO-4578 (EP4 antagonist) in Combination with Opdivo and Chemotherapy Met the Primary Endpoint in a Phase 2 Clinical Trial in Patients with Certain Gastric Cancer
Press Release
October 10, 2025
Ono Pharmaceutical Co., Ltd. Announced Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy
Press Release
October 10, 2025
Ono Pharmaceutical Co., Ltd. Announced 2025 Q1 Financial Results
Management / Finance
August 1, 2025
Ono Pharmaceutical co., ltd. Receives Highest A-List Rating in CDP 2024 Report for Climate Change and Water Security Efforts
Sustainability
July 29, 2025
Ono Pharmaceutical Co., Ltd. Announced 2024 Full Year Financial Results
Management / Finance
May 8, 2025
ONO PHARMA USA Announces 2025 Golden Ticket Competition Now Accepting Applications from Innovative Startups
Press Release
April 25, 2025
Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting
Press Release
April 24, 2025